Position of Scientific Oncological Societies Towards Biosimilar Antibodies | Citedby Results | Breast Care | Karger Publishers

Skip to Main Content

Skip Nav Destination

Position of Scientific Oncological Societies Towards Biosimilar Antibodies

Breast Care (2019) 14 (1): 5–8.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study

Elena A. Christofides
Orlando Puente
Paul Norwood
Douglas Denham
Hiralal Maheshwari
Michael Lillestol
Terence Hart
Samer Nakhle
Anurekha Chadha
David Fitz‐Patrick
Danny Sugimoto
Joseph Soufer
Douglas Young
Mark Warren
David Huffman
John Reed
Harold Bays
Samir Arora
Barbara Rizzardi
Raymond Tidman
Marc Rendell
Kimball A. Johnson

Diabetes, Obesity and Metabolism (2024) 26 (6): 2412.

Biosimilars in oncology: Effects on economy and therapeutic innovations

Kai Hübel
Florian Kron
Michael Patrick Lux

European Journal of Cancer (2020) 139: 10.

Trastuzumab Biosimilars in the Therapy of Breast Cancer – “Real World” Experiences from four Bavarian University Breast Centres

Anna Hester
Paul Gaß
Peter A. Fasching
Anne Katrin Krämer
Johannes Ettl
Joachim Diessner
Achim Wöckel
Tobias Egger
Katja Stock
Jutta Redlin
Monika Andraschko
Nadia Harbeck
Rachel Würstlein

Geburtshilfe und Frauenheilkunde (2020) 80 (09): 924.

Biologicals and Biosimilars in Hematology: The Case of Rituximab

Arnold G. Vulto

HemaSphere (2019) 3 (6): e322.